Scarica l'app Stockscreener
34.29
2.63%
0.88
Dopo l'orario di chiusura:
33.51
-0.78
-2.27%
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com India
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com - Investing.com South Africa
LB Pharmaceuticals names Christopher Zergebel as SVP - Investing.com
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations - GlobeNewswire
Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX) - TradingView
LBRX Forecast — Price Target — Prediction for 2027 - TradingView
LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright - Investing.com
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LB Pharmaceuticals Inc (LBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) Slips 1.28% as Stock Holds Above Key Support — What's Next?Reversal Trade - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) AGM 2026 Summary - Quartr
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
All you need to know about LB Pharmaceuticals Inc (LBRX) rating upgrade to buy - MSN
Clear Street initiates LB Pharmaceuticals stock with buy rating - Investing.com
Clear Street initiates LB Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals Inc (LBRX) Edges Higher Amid Sector Strength – Key Levels in FocusPoint of Control - The Legal Advocate
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target - Investing.com UK
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential - TipRanks
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy - Yahoo Finance
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target By Investing.com - Investing.com Australia
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):